Miao 2025 — co-development of mesoderm and endoderm enables organotypic vascularization in lung and gut organoids (Cell v2)
Deep-read synthesis of Miao Y et al. (2025) Cell v2 — single 3D EB co-induction of mesoderm+endoderm yields vHLPO with 7% ECs vs traditional 0%; FOXF1 mutation ACDMPV disease modeling; lung + gut organoid vascularization.
literature
deep-read
lung-organoid
gut-organoid
vascularization
mesoderm-endoderm
celvivo-clinostar
3brain-hd-mea-adjacent
Miao 2025 — co-development of mesoderm and endoderm enables organotypic vascularization in lung and gut organoids (Cell v2)
Background: Conventional lung and gut organoid protocols differentiate one germ layer at a time — typically endoderm → lung/gut epithelium with mesoderm added separately. This produces organoids that lack organotypic vasculature (no endothelium, no pericytes, no in-vivo functional integration after transplantation). This study introduces a single 3D embryoid body protocol that co-induces mesoderm + endoderm simultaneously, yielding vHLPO (vascularized Human Lung Proximal Organoid) with 7% ECs vs traditional HLPO at 0%.
Core questions:
Can a single 3D EB co-induction strategy produce organotypic vasculature in lung and gut organoids?
Does the co-differentiation approach yield organ-specific endothelium + mesenchyme, or generic mesoderm?
Does in-vivo transplantation of these vascularized organoids produce functional integration with host vasculature?
Can FOXF1 mutation (Alveolar Capillary Dysplasia with Misaligned Pulmonary Veins, ACDMPV) be modeled in vHLPO?
1. Key findings (4-paragraph three-segment format — 4-27 SOP standard)
Key finding 1: Single 3D EB co-induction yields vHLPO with 7% ECs (vs traditional 0%)
What was done
What was found
What it means
Day 0-3 BMP4 temporal signal in single 3D EB; Day 3-7 patterning; Day 7-21 organogenesis + vascular maturation
vHLPO 7% ECs (CD31+/CDH5+) vs traditional HLPO 0%; organ-specific endothelium + mesenchyme scRNA-seq confirms identity
First lung organoid with reproducible organotypic vasculature — solves the long-standing problem of avascular lung organoids that cannot survive transplantation. The co-induction approach is fundamentally different from adding endothelial cells to a pre-formed epithelium
Key finding 2: In vivo functional integration with host circulation
What was done
What was found
What it means
vHLPO transplanted into immunodeficient mouse kidney capsule
Host vessels anastomose with vHLPO vasculature; human CD31+ vessels perfused with mouse blood; survival >4 weeks
vHLPO is not just in-vitro vascularization — it integrates with host circulation in vivo, opening the door to transplantable organoid therapies and disease modeling with systemic drug exposure
Patient-derived iPSC with FOXF1 mutation differentiated via the same protocol
Dual pathology: alveolar type II cell defect + misaligned pulmonary veins + reduced vasculature
ACDMPV (a rare neonatal lethal lung disease) reproduces in vHLPO with both epithelial and vascular pathology — first patient-derived organoid model that captures the full ACDMPV phenotype
vHLPO seeded onto decellularized lung scaffolds and matured 14 days
Alveolar-like structures formed at the scaffold surface; partial alveolar-capillary interface
First proof-of-concept that vascularized organoids + decellularized scaffolds can reconstitute alveolar-capillary architecture — bridges 3D bioprinting (the scaffold) and organoid technology (the cellular component)
2. Methodology
Step
Content
Key parameters
1. Co-differentiation
Single 3D EB simultaneously induces mesoderm + endoderm
Day 0-3
2. BMP temporal
BMP4 temporal signal decides anterior-posterior axis fate
BMP temporal signal validated only in this lung/gut model — not yet confirmed in other organoid types (brain, liver, kidney). Generalizability unknown.
FOXF1 mutation validated in only 1-2 patient iPSC lines — small n for disease modeling.
Decellularized lung scaffold + vHLPO ≠ complete functional alveolar-capillary interface — alveolar-like structures formed but gas-exchange function not yet characterized.
Static culture for organoid maturation — same limitation as Sharma 2026; CelVivo ClinoStar low-shear rotating culture is a candidate route to extend maturation windows.
4. Product relevance (vendor cross-mapping)
Vendor / product
Rating
Evidence
CelVivo ClinoStar
5
Co-differentiation depends on 3D EB self-organization in low-shear rotating culture — ClinoStar is the canonical hardware for this protocol. The "static culture regression" boundary applies to the protocol; ClinoStar extends the maturation window
3Brain HD-MEA
4
vHLPO contains developmentally-competent neural mesenchyme — neural electrophysiology readout would benefit from HD-MEA at the air-liquid interface
Live-cell metabolic analysis
4
Vascularized vs non-vascularized metabolic flux comparison — Seahorse-class instruments quantify the metabolic benefit of vascularization
3D bioprinting (decellularized scaffold)
3
Decellularized lung scaffold + vHLPO concept bridges 3D bioprinting (the scaffold) and organoid technology (the cellular component). Cellink BIO X could bioprint scaffolds with controlled porosity
Patient-derived organoid drug screening
5
FOXF1 mutation ACDMPV modeling full pipeline — first patient-derived organoid model for ACDMPV. Same workflow applies to other rare disease FOXF1-class mutations
5. Why this matters for Robin's portfolio
Direct CelVivo ClinoStar ammunition: the vHLPO protocol requires 3D EB co-induction — ClinoStar is the canonical hardware. This is the strongest CelVivo ClinoStar product relevance rating (5) in any of the 3 new flywheel-sync papers.
Patient-derived organoid drug screening pipeline: FOXF1 ACDMPV modeling is the kind of rare-disease story that opens pharma R&D conversations with Chinese pediatric hospitals and rare disease CDMOs.
Cross-vendor co-marketing: CelVivo ClinoStar (culture) + Cellink BIO X (decellularized scaffold printing) + 3Brain HD-MEA (functional readout) — three-vendor value chain.
Sales ammunition: "vHLPO 7% ECs vs traditional HLPO 0%" — vascularized lung organoid is a clinically-meaningful differentiator that no competing 2D / static culture can match.
6. Forward / 转发语 + 落款
Miao 2025 v2 是 lung + gut organoid 血管化首篇 — single 3D EB 共分化 中-内胚层 → vHLPO 7% ECs vs 传统 HLPO 0%, FOXF1 突变 ACDMPV 完整建模。CelVivo ClinoStar 是 canonical 硬件 (rating 5), 患者源类器官药筛完整管线建立。
— Robin 8-08 精读 v2
Cross-reference
Canonical synthesis: this page (/sources/literature-miao-2025-cell-vascularization-v2-deepread.md)
OpenWiki Bot